Videos

Michail Ignatiadis, MD, PhD, Jules Bordet Institute

Videos

No Benefit From Addition of Atezolizumab to Adjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer

12/07/2023

Featuring Michail Ignatiadis, MD, PhD

Featuring Michail Ignatiadis, MD, PhD...

Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.

Michail Ignatiadis, MD, PhD,...

12/07/2023

Oncology

Conference Coverage

Front-Line Treatment Options for Ovarian Cancer

12/07/2023

Featuring Bradley Monk, MD

At the Great Debates & Updates in Women’s Oncology meeting, Bradley Monk, MD, discussed molecular testing and advancements in front-line treatment for patients with advanced epithelial ovarian cancer.

At the Great Debates & Updates...

12/07/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previously Treated, Inoperable, or Metastatic HR-Positive, HER2-Negative Breast Cancer

12/07/2023

Featuring Aditya Bardia, MD, MPH

Featuring Aditya Bardia, MD, MPH ...

Aditya Bardia, MD, MPH, discussed results from the TROPION-Breast01 trial comparing datopotamab deruxtecan, a TROP-2 directed antibody drug conjugate, with standard chemotherapy in endocrine-resistant metastatic breast cancer.

Aditya Bardia, MD, MPH,...

12/07/2023

Oncology

Conference Coverage

Palbociclib Plus Fulvestrant or Letrozole for HR-Positive, HER2-Negative Advanced Breast Cancer

12/07/2023

Featuring Antonio Llombart-Cussac MD, PhD

Featuring Antonio Llombart-Cussac MD,...

Antonio Llombart-Cussac MD, PhD, discussed extended follow-up results from the phase 2 PARSIFAL study combining the CDK4/6 inhibitor palbociclib with either fulvestrant or letrozole.

Antonio Llombart-Cussac MD, PhD,...

12/07/2023

Oncology

Conference Coverage

Efficacy, Safety of Toripalimab Plus Metronomic Chemotherapy for HER2-Negative Metastatic Breast Cancer

12/07/2023

Featuring Hongnan Mo, MD

Hongnan Mo, MD, discussed results from a phase 2 study comparing metronomic chemotherapy plus PD-1 blockade to combined conventional chemotherapy plus immune checkpoint blockade.

Hongnan Mo, MD, discussed...

12/07/2023

Oncology

Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Videos

Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer

12/07/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 2 of...

12/07/2023

Oncology

Sara Hurvitz, MD, Fred Hutchinson Cancer Center

Videos

Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer

12/06/2023

Featuring Sara Hurvitz, MD

Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.

Sara Hurvitz, MD, shares results...

12/06/2023

Oncology

Videos

Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer

11/30/2023

Featuring Cynthia Ma, MD; Neelima Vidula, MD; and Seth Wander, MD

Featuring Cynthia Ma, MD; Neelima Vid...

Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...

Cynthia Ma, MD, leads part 1 of...

11/30/2023

Oncology

Videos

Evaluating the Addition of Ibrutinib to Standard Chemotherapy for Follicular Lymphoma or MZL

11/27/2023

Featuring Gilles Salles, MD, PhD

Featuring Gilles Salles, MD, PhD ...

Gilles Salles, MD, PhD, highlights findings from the phase 3 SELENE trial, which aimed to assess the value of adding ibrutinib to chemotherapy among patients with previously treated follicular lymphoma or marginal zone lymphoma.

Gilles Salles, MD, PhD,...

11/27/2023

Oncology

Videos

Minimizing Risk of Adverse Events and Transformation Among Patients With Follicular Lymphoma

11/27/2023

Featuring Abhay Singh, MD

Abhay Singh, MD, shares advice for fellow oncologists treating patients with follicular lymphoma aiming to minimize the risk of adverse events and disease transformation to AML/MDS.

Abhay Singh, MD, shares advice...

11/27/2023

Oncology

Videos

Specialties

Specialties

Events

Year Round Education

HMP Global Products